Type

Journal Article

Authors

Michael J Duffy
Alan R Fersht
John Crown
William M Gallagher
Darran O'Connor
Norma O'Donovan
Rut Klinger
Alyson Murray
Stephen Madden
Matthias R Bauer
and 1 others

Subjects

Pharmacology

Topics
p53 cancer cell lines cancer treatment therapeutic triple negative breast cancer anti cancer mutant drug treatment

Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007. (2017)

Abstract The identification of a targeted therapy for patients with triple-negative breast cancer (TNBC) is one of the most urgent needs in breast cancer therapeutics. The p53 gene is mutated in approximately 80% of patients with TNBC, and is a potential therapeutic target for patients with this form of breast cancer. The 2-sulfonylpyrimidine compound, PK11007, preferentially decreases viability in p53-compromised cancer cell lines. We investigated PK11007 as a potential new treatment for TNBC. IC
Collections Ireland -> Dublin City University -> PubMed

Full list of authors on original publication

Michael J Duffy, Alan R Fersht, John Crown, William M Gallagher, Darran O'Connor, Norma O'Donovan, Rut Klinger, Alyson Murray, Stephen Madden, Matthias R Bauer and 1 others

Experts in our system

1
Michael J Duffy
University College Dublin
 
2
John Crown
Dublin City University
Total Publications: 104
 
3
William M Gallagher
University College Dublin
Total Publications: 148
 
4
Darran P O'Connor
Royal College of Surgeons in Ireland
Total Publications: 43
 
5
Norma O'Donovan
Dublin City University
Total Publications: 59
 
6
Alyson Murray
Dublin City University
Total Publications: 6
 
7
Stephen F Madden
Dublin City University
Total Publications: 45